X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare J.B.Chemicals with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

J.B.CHEMICALS vs SANOFI INDIA - Comparison Results

J.B.CHEMICALS    Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    J.B.CHEMICALS SANOFI INDIA J.B.CHEMICALS/
SANOFI INDIA
 
P/E (TTM) x 17.1 39.9 42.9% View Chart
P/BV x 2.3 8.6 26.9% View Chart
Dividend Yield % 0.2 1.0 15.9%  

Financials

 J.B.CHEMICALS   SANOFI INDIA
EQUITY SHARE DATA
    J.B.CHEMICALS
Mar-16
SANOFI INDIA
Dec-16
J.B.CHEMICALS/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs3184,560 7.0%   
Low Rs2004,400 4.5%   
Sales per share (Unadj.) Rs148.01,028.5 14.4%  
Earnings per share (Unadj.) Rs19.1129.0 14.8%  
Cash flow per share (Unadj.) Rs23.9186.0 12.9%  
Dividends per share (Unadj.) Rs0.5068.00 0.7%  
Dividend yield (eoy) %0.21.5 12.7%  
Book value per share (Unadj.) Rs128.9753.6 17.1%  
Shares outstanding (eoy) m84.8223.03 368.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.74.4 40.2%   
Avg P/E ratio x13.634.7 39.0%  
P/CF ratio (eoy) x10.824.1 44.9%  
Price / Book Value ratio x2.05.9 33.8%  
Dividend payout %2.652.7 5.0%   
Avg Mkt Cap Rs m21,951103,174 21.3%   
No. of employees `0002.73.6 75.5%   
Total wages/salary Rs m1,8413,592 51.3%   
Avg. sales/employee Rs Th4,590.96,537.7 70.2%   
Avg. wages/employee Rs Th673.4991.4 67.9%   
Avg. net profit/employee Rs Th592.1819.8 72.2%   
INCOME DATA
Net Sales Rs m12,55123,686 53.0%  
Other income Rs m542708 76.5%   
Total revenues Rs m13,09324,394 53.7%   
Gross profit Rs m2,0555,281 38.9%  
Depreciation Rs m4121,313 31.4%   
Interest Rs m9615 638.0%   
Profit before tax Rs m2,0884,661 44.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4691,691 27.7%   
Profit after tax Rs m1,6192,970 54.5%  
Gross profit margin %16.422.3 73.4%  
Effective tax rate %22.536.3 61.9%   
Net profit margin %12.912.5 102.9%  
BALANCE SHEET DATA
Current assets Rs m7,77815,673 49.6%   
Current liabilities Rs m4,3586,678 65.3%   
Net working cap to sales %27.238.0 71.7%  
Current ratio x1.82.3 76.0%  
Inventory Days Days5576 71.9%  
Debtors Days Days8022 358.6%  
Net fixed assets Rs m5,7138,098 70.5%   
Share capital Rs m170230 73.6%   
"Free" reserves Rs m10,54717,088 61.7%   
Net worth Rs m10,93717,356 63.0%   
Long term debt Rs m00-   
Total assets Rs m15,57425,400 61.3%  
Interest coverage x22.8311.7 7.3%   
Debt to equity ratio x00-  
Sales to assets ratio x0.80.9 86.4%   
Return on assets %11.011.8 93.7%  
Return on equity %14.817.1 86.5%  
Return on capital %20.026.9 74.1%  
Exports to sales %48.724.5 198.9%   
Imports to sales %7.128.0 25.3%   
Exports (fob) Rs m6,1155,801 105.4%   
Imports (cif) Rs m8896,627 13.4%   
Fx inflow Rs m6,1697,145 86.3%   
Fx outflow Rs m1,2856,846 18.8%   
Net fx Rs m4,884299 1,633.4%   
CASH FLOW
From Operations Rs m1,3973,226 43.3%  
From Investments Rs m-320-1,555 20.6%  
From Financial Activity Rs m-1,196-1,818 65.8%  
Net Cashflow Rs m-102-147 69.6%  

Share Holding

Indian Promoters % 55.4 0.0 -  
Foreign collaborators % 0.3 60.4 0.5%  
Indian inst/Mut Fund % 3.4 14.4 23.5%  
FIIs % 3.9 14.6 26.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 37.0 10.5 352.4%  
Shareholders   30,437 15,184 200.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare J.B.CHEMICALS With:   FULFORD INDIA  VENUS REMEDIES  STERLING BIOTECH  CADILA HEALTHCARE  AUROBINDO PHARMA  

Compare J.B.CHEMICALS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY18); Net Profit Up 37.5% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, SANOFI INDIA has posted a net profit of Rs 825 m (up 37.5% YoY). Sales on the other hand came in at Rs 6 bn (up 11.7% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

J.B.CHEMICALS SHARE PRICE


Sep 21, 2018 (Close)

TRACK J.B.CHEMICALS

  • Track your investment in J.B.CHEMICALS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

J.B.CHEMICALS - ELDER PHARMA COMPARISON

COMPARE J.B.CHEMICALS WITH

MARKET STATS